Andrew Schwerin is an associate in the firm’s intellectual property (IP) practice, where he focuses on complex patent litigation and IP counseling. Mr. Schwerin’s practice includes a variety of technologies, including small molecule therapeutics; biologics, including vaccines and antibodies; and medical devices.
Practice & Background
Prior to law school, Mr. Schwerin worked for several years as an analyst for two major prior art search firms. In 2012, he began law school at Rutgers University School of Law. In law school, Mr. Schwerin was a participant in the moot court and mock trial teams; he was also submissions editor on the Rutgers Journal of Law and Public Policy. In 2014, he was admitted to practice before the United States Patent and Trademark Office; while still in school, he worked part-time as a patent agent at a major law firm. He graduated magna cum laude in 2015.
Mr. Schwerin’s recent engagements include:
- representing a major medical device manufacturer in a trade secret and breach-of-contract action (arbitration; D. Mass.)
- representing a pharmaceutical company in a patent infringement suit involving PD-1 antibodies; succeeded in obtaining a favorable settlement for the client (D. Del)
- representing a pharmaceutical company in a patent infringement suit involving the meningitis B vaccine; succeeded in obtaining a favorable settlement resolving the matter (D.N.J.)
- advising a pharmaceutical company on its patent portfolio prior to commercial launch.
- Mr. Schwerin has also assisted clients in a variety of pro bono matters, including asylum/refugee cases, exceptional-scholar visas and juvenile-defendant resentencing hearings.
- Mr. Schwerin is an active member of the Ben Franklin American Inn of Court and the New Jersey Intellectual Property Law Association.